Cervical cancer diagnoses among rural U.S. women have been increasing since 2012, after years of decreases, according to research from MUSC Hollings Cancer Center and the University of Texas MD Anderson Cancer Center.
A recent study led by researchers at the University of Arizona Cancer Center and Northern Arizona University found that Native American women were disproportionately affected by vaginal dysbiosis, a disruption in the balance of bacterial that increases the risk of human papillomavirus infection, which can cause cervical cancer.
The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.
Bintrafusp alfa, a novel bispecific antibody, achieved an objective response rate of 22% in women with recurrent or metastatic cervical cancer in a phase II nonrandomized controlled trial.
Harnessing the power of CRISPR gene-editing technology in a new way, University of Florida researchers have created a one-tube testing method targeting DNA from body fluids that has the potential to dramatically increase access to the diagnosis of viral diseases such as cervical cancer.
A research team from Louisiana State University LCMC Health Cancer Center has been awarded a $1.5 million grant to eliminate barriers from cervical cancer prevention.
FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.
FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk, locally advanced cervical cancer.
In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining.
St. Jude’s Path to a Bright Future, an HPV awareness and vaccination campaign with nearly 160 partners, is aimed at reducing that disease burden by targeting children in a crucial age range.
